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Abstract
Intracellular transport of cholesterol contributes to the regulation of cellular cholesterol homeostasis by mechanisms that
are yet poorly defined. In this study, we characterized the impact of dynasore, a recently described drug that specifically
inhibits the enzymatic activity of dynamin, a GTPase regulating receptor endocytosis and cholesterol trafficking. Dynasore
strongly inhibited the uptake of low-density lipoprotein (LDL) in HeLa cells, and to a lower extent in human macrophages. In
both cell types, dynasore treatment led to the abnormal accumulation of LDL and free cholesterol (FC) within the
endolysosomal network. The measure of cholesterol esters (CE) further showed that the delivery of regulatory cholesterol to
the endoplasmic reticulum (ER) was deficient. This resulted in the inhibition of the transcriptional control of the three major
sterol-sensitive genes, sterol-regulatory element binding protein 2 (SREBP-2), 3-hydroxy-3-methyl-coenzymeA reductase
(HMGCoAR), and low-density lipoprotein receptor (LDLR). The sequestration of cholesterol in the endolysosomal
compartment impaired both the active and passive cholesterol efflux in HMDM. Our data further illustrate the importance of
membrane trafficking in cholesterol homeostasis and validate dynasore as a new pharmacological tool to study the
intracellular transport of cholesterol.
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Introduction
Membrane trafficking contributes to cell cholesterol homeostasis
through the control of intracellular cholesterol levels and
compartmentalization. Little is known about the transport
pathways involved in cholesterol trafficking and the associated
molecular machinery [1]. The level of cellular cholesterol results
from the tight control of both cholesterol neosynthesis and low-
density lipoprotein (LDL)-derived cholesterol uptake. The uptake
of LDL-derived cholesterol at the plasma membrane occurs
primarily through clathrin-dependent endocytosis of the low-
density lipoprotein receptor (LDLR), as shown in the seminal
studies by Brown and Goldstein [2]. This process delivers
lipoprotein-associated cholesterol esters (CE) first to the early
endosome (EE) and then to the late endosomal/lysosomal
network. At this stage, the acid hydrolases de-esterify CE into
free cholesterol (FC), which will leave the endolysosomal network
to reach the endoplasmic reticulum (ER) either directly or
indirectly after transiting through the Golgi apparatus and the
plasma membrane [3]. ER membranes, which are characterized
by a poor content in cholesterol, are home to the principal
effectors of cellular cholesterol homeostasis. Key of this regulation
is a family of membrane-bound transcription factors, sterol
regulatory element binding proteins (SREBPs). Under low sterol
concentration, SREBP is transported to the Golgi complex where
it is activated by proteolytic processing. This cleavage releases the
active form of SREBP, which is translocated to the nucleus where
it regulates the transcription of sterol responsive genes involved in
cholesterol synthesis (3-hydroxy-3-methyl-coenzymeA reductase
(HMGCoAR)) or uptake (LDLR) [4]. Cholesterol transport to the
ER is therefore a key element of the cholesterol homeostasis
machinery. The levels of cholesterol are constantly monitored by
the two chaperone proteins SCAP (SREBP cleavage activating
protein) and INSIG (insulin-induced gene protein). SCAP is a
SREBP Golgi escort protein while INSIG is an ER anchored
protein. Binding of cholesterol or oxysterols to SCAP or to INSIG,
respectively, promotes the interaction between SCAP and INSIG.
The formation of this complex masks the binding site on SCAP
that is recognized by the vesicular coat transport complex COPII,
thereby blocking SREBP transport from the ER to the Golgi
apparatus and the release of the cleaved SREBP active form [5,6].
Another important actor of this tight regulation is the acyl
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ER [7]. ACAT rapidly esterifies FC in CE to be stored in
cytoplasmic lipid droplets, in response to an increased concentra-
tion of cholesterol in the ER. ACAT activity is therefore required
for decreasing the amount of cytotoxic FC and for maintaining a
low level of cholesterol in the ER membranes, such that minimal
variations of sterol concentrations can be sensed. In some cases,
ER-derived vesicular structures that are positive for ACAT can
also be involved in this process. It has been proposed that these
structures, which are distinct from the conventional ER, may
protect the non-fragmented ER from being overloaded with
cholesterol [8].
The GTPase dynamin is a mechano-chemical enzyme required
for the pinching and release of a completed clathrin-coated pit
from the plasma membrane. In HeLa cells expressing the K44A
inactivated form of dynamin, we have revealed a new role for
dynamin in the delivery of endolysosomal FC to the ER [9]. The
inactivation of dynamin led to a Niemann-Pick type C-like
phenotype (NPC) with the accumulation of swollen late endo-
somes/lysosomes (LE/LS) engorged with FC. Dynamin inactiva-
tion was also associated with a strong reduction of sterol-sensitive
genes regulation and a decrease of the esterification of the
intracellular pool of cholesterol by ACAT. If K44A HeLa cells are
an easily amenable cell model, we sought to study the role of
dynamin in more physiologically relevant cell types such as
macrophages, which play a key role in atherosclerosis. However
there are technical limitations to obtain macrophages expressing
the inactivated form of dynamin. We therefore took advantage of
the membrane permeant chemical compound, dynasore, a
recently described noncompetitive inhibitor of the GTPase activity
of dynamin [10,11]. Dynasore presents also the advantage to act
within minutes and to have a completely reversible activity. To
validate the use of this new drug, we studied the impact of
dynasore on critical steps of cholesterol trafficking in both HeLa
cells and HMDM. We show here that dynasore rapidly inhibits the
egress of free cholesterol from the endolysosomal network in these
two cell types. As a result, the sterol-sensitive gene regulation of
cholesterol homeostasis is inhibited. Dynasore is therefore a new
drug that will be useful for further understanding cholesterol
endosomal trafficking, a key step in cholesterol homeostasis.
Materials and Methods
Cells and reagents
HeLa cells were cultured in Dulbecco modified Eagle’s medium
(DMEM) with 10% heat-inactivated fetal calf serum (FCS)
(Invitrogen, Cergy-Pontoise, France), 2 mM glutamine, 100 UI/
ml penicillin, 100 mg/ml streptomycin (Sigma-Aldrich, St Louis,
MO). Cells were treated with dynasore (Sigma-Aldrich) at 80 mM
in the presence of 1% lipoprotein-deficient serum (LPDS) medium
to avoid inactivation of dynasore by serum proteins. U18666A
(Sigma-Aldrich) was used at 3 mg/ml in 1% LPDS medium.
Monocytes were isolated from human blood of normolipidemic
donors by ficoll density gradient (Eurobio, les Ulis, France) and
subsequently differentiated into human monocytes-derived mac-
rophages (HMDM) by adhesion on plastic Primaria plates (Falcon
BD, Franklin Lakes, NJ,) for 7 days in RPM1640 medium,
supplemented with 10% heat-inactived FCS, 2 mM glutamine,
100 UI/ml penicillin, 100 mg/ml streptomycin, and 20 ng/ml
hM-CSF (human macrophages colony-stimulating factor) (AbCys,
Paris, France).
HeLa cells expressing a GFP tagged M6PR were described in
[12]. Cells were cultured in Dulbecco modified Eagle’s medium
(DMEM) with 10% heat-inactivated fetal calf serum (FCS)
(Invitrogen,), 2 mM glutamine, 100 UI/ml penicillin, 100 mg/ml
streptomycin (Sigma-Aldrich,) completed with geneticin. They
were treated with dynasore the same way that HeLa cells.
Antibodies
The mouse anti-human Lamp-1 antibody was from BD
Transduction Laboratories. Primary antibodies were revealed by
incubation with Alexa FluorH488 donkey anti-mouse IgG
(Invitrogen).
Cholesterol delivery to the cell
Human LDL (d=1.019–1.063 g/ml) were separated from fresh
plasma by sequential ultracentrifugation as described previously
[9]. HeLa cells deprived of sterols for 48 h in 10% LPDS medium
were incubated for the indicated times with LDL (200 mg/ml),
supplemented with 50 mM pravastatin and 50 mM sodium
mevalonate. HMDM were incubated with 50 or 100 mg/ml of
acetylated LDL (AcLDL) prepared using the standard acetic
anhydride-sodium acetate solution on ice as described [13].
LDL and AcLDL labeling
LDL were labeled with DiI (1,19-dioctadecyl-3,3,3939-tetra-
methyl-indocarbocyanine) as described previously [14]. Briefly,
DiI were added to LDL to a final ratio of 300 mg for 1 mg LDL
protein. After incubation for 18 h at 37uC under nitrogen and
light protection, DiI-labeled LDL were isolated by ultracentrifu-
gation and extensively dialyzed at 4uC against PBS (Eurobio). For
DiI-AcLDL production, AcLDL were first labeled with DiI and
acetylated.
LDL uptake assay
LDL uptake was described in [9]. Briefly, cells grown in LPDS
medium during 48 h were washed in PBS and incubated at 37uC
with increasing concentrations of DiI-LDL (HeLa cells) or DiI-
AcLDL (HMDM) as indicated. After 4 h, cells were treated by
trypsin to remove cell surface bound fluorescent LDL. Cells were
detached and washed twice in PBS at 4uC. The fluorescence of
internalized DiI-LDL or DiI-AcLDL was measured by flow
cytometry (emission at 585 nm) and expressed as mean fluores-
cence intensity.
Measurement of cellular cholesterol
After 48 h of culture in LPDS medium, cells were incubated for
6 h with 200 mg/ml LDL (HeLa cells) or 50 mg/ml AcLDL
(HMDM) and then lysed in 0.2 M NaOH. Total cholesterol was
extracted with methanol (2.5 ml) followed by hexane (5 ml). About
4.5 ml of the hexane phase was evaporated under vacuum and
dissolved in mobile phase. Separation of FC and CE including
cholesteryl docohexanoate (CDH), cholesteryl arachidonate (CA),
cholesteryl linoleate (CL), cholesteryl myristate (CM), cholesteryl
oleate (CO) and cholesteryl stearate (CS) was done by reverse
phase HPLC on a C-18 column (2560.46 cm length, 5-mm pore
size, Sigma-Aldrich) by measuring the 205 nm absorbance after
elution with acetonitrile/isopropanol (30/70, v/v) [15,16]. The
amount of proteins present in cell lysates and LDL preparations
was measured using the bicinchoninic acid (BCA) method [17].
ACAT activity
120 mM sodium myristate (Sigma-Aldrich) was added during
cholesterol delivery to the cells. The ACAT enzyme activity was
evaluated by quantifying the incorporation of myristate into
cholesteryl myristate by HPLC as described above. The ACAT
inhibitor Sandoz 58-035 (Sigma-Aldrich) (10 mg/ml) was added to
Dynasore Impairs Cholesterol Homeostasis
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29042the cholesterol loading medium. When ACAT activity is inhibited,
CE are provided by pre-existing pools such as endocytosed LDL.
Therefore, the difference in cholesterol esterification measured by
HPLC with and without Sandoz 58-035 represents the specific
amount of cholesterol esterified by ACAT.
Cellular cholesterol mass efflux to apoA-I and HDL in
cholesterol-loaded macrophages
After treatment with dynasore or U18666A, HMDM were
equilibrated in RPMI1640 0.2% BSA for 16 h in the presence or
not of 5 mg/ml 22-hydroxy-cholesterol (22OH-C) and 10 mM 9-cis
retinoic acid (9cRA) (Sigma-Aldrich). Cellular cholesterol efflux to
either 1 mg/ml methyl-b-cyclodextrin (MbCD), 10 mg/ml lipid-
free apoA-I (Sigma-Aldrich) or 15 mg/ml high-density lipoprotein-
phospholipids (HDL-PL isolated from normolipidemic human
plasma by preparative ultracentrifugation) was measured during a
4 h chase period. Drugs were maintained during the equilibration
and efflux periods. At the end of the efflux, the medium was
collected and the cells lysed in 0.2 M NaOH. Cell and media were
extracted and analyzed for free and esterified cholesterol mass by
HPLC as described above. HDL samples were separately analyzed
to allow correction for HDL cholesterol present in relevant media
samples. Mass cholesterol efflux is expressed as the percentage of
efflux (medium cholesterol over total cholesterol-medium and cells)
[18].
Immunofluorescence
Analysis of LDL-derived cholesterol trafficking was performed
by immunofluorescence as described [9]. Briefly, HeLa cells and
HMDM were grown on cover slips for 48 h in LPDS medium. To
monitor LDL trafficking, cells were incubated with fluorescent
LDL for indicated times. Cells were incubated with 200 mg/ml
LDL or 50 mg/ml AcLDL and then stained with filipin (50 mg/ml)
to detect FC as described [19]. Cells were fixed in 4%
paraformaldehyde (PFA) in PBS. For immunolocalization studies,
cells were incubated with primary and secondary antibodies
diluted in PBS/BSA with saponin. Cover slips were mounted in
MOWIOL, and cells were imaged with an epifluorescent Leica
microscope.
RNA extraction, RT-PCR and real time quantitative PCR
Total RNA was extracted from HeLa cells using the RNeasy
Mini kit (Qiagen, Courtaboeuf, France). One microgram of total
RNA was transcribed to cDNA using random hexamers
(Amersham, Orsay, France) and SuperScriptII reverse transcrip-
tase (Invitrogen). Specific primers were described previously [9].
Figure 1. Effect of dynasore on LDL uptake and total cholesterol in HeLa cells and HMDM. Cells were incubated for 4 h with 0–200 mg/ml
DiI-LDL (A) or 0–100 mg/ml DiI-AcLDL (C) at 37uC with 0.4% v/v DMSO (control) or 80 mM dynasore. The total amount of endocytosed DiI-LDL or DiI-
AcLDL was measured by flow cytometry. Values represent the mean 6 SD of triplicate experiments. Total cholesterol was quantified in HeLa cells (B)
and HMDM (D) after 4 h of LDL uptake with 0.4% v/v DMSO (control) or 80 mM dynasore. Each value is the mean 6 SD of triplicate experiments and
expressed as nanomoles per mg of cell proteins.
doi:10.1371/journal.pone.0029042.g001
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SybrH Green reagents kit (Applied Biosystems, Courtaboeuf,
France) with an ABI PRISM 7900HT Sequence detector
instrument (Applied Biosystems) according to the manufacturer’s
instructions. Amplification was carried out in a final volume of
10 mL with 20 ng of reverse transcribed total RNA, 150 nM
(HMGCoAR, LDLR) or 300 nM (UBC and SREBF-2) of both
sense and antisense primers (Eurogentec, Lie `ge, Belgium) in the
SybrH Green PCR Master Mix (MESA GREEN qPCR,
Eurogentec). The cycling conditions comprised 40 cycles at
95uC for 15 s and 60uC for 1 min. Relative quantification for a
given gene, expressed as fold-variation over control at T0, was
calculated after normalization to a reference gene (UBC) and
determination of the CT (cycle threshold) difference between
conditioned cells and control cells at T0 using the comparative CT
method [20]. Efficiencies of the target and control amplification
were very similar.
Dynamin 2 RNAi Treatment
Non targeting siRNA (si scramble) and siRNA against
dynamin2 (si Dyn2) (GGA CAU GAU CCU GCA GUUdTdT)
were described in [21]. Briefly, HeLa cells were transfected using
RNAiMAX (Invitrogen) according to the manufacturer’s instruc-
tions. Knockdown of Dyn2 was observed 48 h post-treatment.
Cells transfected with scramble siRNA were used as a control.
Western Blotting
Cells were lysed in 1% triton 6100 in PBS containing protease
inhibitors. Proteins (30 mg per lane) were separated on a 3–8%
NuPAGE in Tris acetate gels (Invitrogen) and transferred to a
PDVF membrane (Bio-Rad, Hercules, CA). The membrane was
incubated for 1 h in blocking solution (5% nonfat dry milk, 0.1%
Tween 20 in PBS). Dynamin 2 was detected using mouse
monoclonal anti-dynamin 2 (Invitrogen). A rabbit anti-b-actin
polyclonal antibody was used as loading control (Sigma).
Development was performed with chemiluminescent detection
kit (ECL, Amersham Life Science).
Results
Dynasore inhibits the uptake of LDL cholesterol in HeLa
cells and human macrophages
We tested the effect of dynasore on HeLa cells, where dynamin
was first reported to control CT trafficking [9]. Dynasore was
tested at 80 mM, the concentration shown to efficiently block the
internalization of the transferrin receptor [10]. We measured the
uptake of fluorescently labeled human LDL by flow cytometry.
Dynasore treatment led to a strong inhibition of LDL uptake at
10 mg/ml with less than 10% of the uptake level measured in
untreated cells (Figure 1A). For comparison, the uptake of LDL
was decreased by about 50% in our previous study with HeLa cells
expressing the K44A inhibitory mutant of dynamin [9]. The
continuous uptake of LDL for 6 hours in sterol-starved cells led to
a 2.5 fold increase of the total amount of cellular cholesterol – free
and esterified – as measured by HPLC in control cells. Despite the
strong inhibition of LDL uptake, there was still an increase albeit
more moderate in dynasore-treated cells (50615 and 4368 nmol/
Figure 2. Effects of dynasore on the intracellular distribution of
FC and LDL in HeLa cells and HMDM. (A) Hela cells were loaded
with 200 mg/ml LDL for 24 h. Cells were then treated for 6 h with 80 mM
dynasore or without (control) and stained with filipin to detect FC. (B)
Cells were treated as described above with 200 mg/ml DiI-LDL. (C)
HMDM were incubated for 6 h in LPDS medium containing 50 mg/ml
DiI-AcLDL with 80 mM dynasore or without (control). (D) HMDM were
loaded with 50 mg/ml DiI-AcLDL for 24 h and then treated for 6 h with
80 mM dynasore or without (control). Images were obtained using wide-
field epifluorescence microscopy. Scale bars, 10 mm.
doi:10.1371/journal.pone.0029042.g002
Figure 3. Dynasore treatment results in the endolysosomal
accumulation of FC and LDL in HeLa cells. Cells were treated for
6 h with 80 mM dynasore or without (control) in medium containing
200 mg/ml LDL (A) or DiI-LDL (B) and processed for filipin staining (A) or
DiI-LDL detection (B). Left panels present Lamp1 staining. Merge of
Lamp1 with FC (A) or with DiI-LDL (B) is shown in the right panel. Scale
bars, 10 mm.
doi:10.1371/journal.pone.0029042.g003
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our findings in HeLa cells that cholesterol can enter cells through
other dynamin-independent endocytic pathways [9]. We next
characterized dynasore in HMDM since they play a central role in
the formation and progress of atherosclerotic plaques [22]. The
uptake of AcLDL in HMDM was twice as much less efficient than
the uptake of LDL in HeLa cells (Figure 1C). The effect of
dynasore was less important in HMDM since the uptake of
AcLDL uptake was decreased by 50% at 10 mg/ml and by 17% at
100 mg/ml. However, the absolute amount of endocytosed
cholesterol was similar in HeLa cells and HMDM treated by
dynasore. In agreement with the lower inhibition of AcLDL
uptake, the measure of the total amount of cholesterol revealed no
difference between control and dynasore-treated HMDM
(Figure 1D).
Dynasore blocks the egress of free cholesterol from the
late endosomal network in HeLa cells and human
macrophages
We examined the intracellular distribution of FC derived from
endocytosed LDL using filipin, a naturally fluorescent antibiotic
that binds selectively to the FC fraction present in cellular
membranes. We also visualized the intracellular distribution of
DiI-LDL since we showed previously that DiI-LDL undergo the
same endocytic and degradative processes than unlabeled LDL
[9]. Cells were incubated with LDL for 24 hours to allow their
distribution within the different endosomal compartments along
the endocytic pathway. In control cells, FC was found into small
endosomal structures within the cytoplasm of the cell (Figure 2A).
A similar pattern was found for DiI-LDL (Figure 2B). Upon
dynasore treatment, we could observe the accumulation of FC and
Internalized DiI-LDL into numerous enlarged endosomes
(Figures 2 A and B). We also examined the intracellular
distribution of DiI-AcLDL in HMDM after 6 hours of internal-
ization. Dynasore treatment led also to an increase of both the
number and the size of the endosomal structures loaded with DiI-
AcLDL (Figure 2C). This effect was enhanced when cells were first
incubated with DiI-AcLDL for 24 hours before the addition of
dynasore (Figure 2D). These endosomes were part of the late
endosomal network since they were positive for the lysosomal
associated membrane protein 1 (Lamp1), a marker of late
endosomes and lysosomes (Figures 3 A and B). Thus, dynasore
which blocks the GTPase activity of dynamin, causes the
accumulation of endocytosed LDL-derived cholesterol in the late
endocytic compartment and prevents its egress from this
compartment in both HeLa and HMDM cells. This is in
agreement with our previous study showing that dynamin controls
the delivery of cholesterol from late endosomes to the ER in HeLa
cells [9]. The abnormal endosomal accumulation of LDL was
already observed after 15 min of dynasore treatment indicating
that dynasore acts at the endoslysosomal level in the same order of
time that it requires to inhibit the uptake of transferrin and LDL at
the plasma membrane (data not shown) [10].
Down-expression of dynamin results in the inhibition of
free cholesterol egress from the late endosomal network
To confirm the specificity of dynasore treatment, we depleted
endogenous dynamin 2, the major dynamin isoform expressed in
HeLa cells using specific siRNA. Dyn2 siRNa treatment led to a
strong down-expression of dynamin 2 as assessed by real time
quantitative RT-PCR (data not shown) and western blot analysis
(Figure 4A). Under this treatment, there was an accumulation of
swollen endosomal structures loaded with LDL or FC, and positive
for Lamp1 (Figure 4 B and C). These results faithfully reproduce
the phenotype observed with dynasore treatment and therefore
exclude dynasore side effects at the endosomal interface.
Dynasore prevents the down-regulation of sterol-
sensitive genes induced by exogenous LDL-derived
cholesterol
The delivery of FC from the late endolysosomal compartment
to the ER is a key process in the transcriptional regulation of
sterol-sensitive genes [1,7,9]. We therefore studied whether
dynasore had an impact on this regulation. In contrast to the
conditional K44A HeLa cell line that requires 48 hours to express
the K44A dynamin mutant [9], dynasore is active within a few
minutes. We thus determined the minimal amount of time
required to measure an effect of dynasore on the expression of the
LDLR gene, one of the major actors of the transcriptional control
Figure 4. Dynamin silencing leads to endolysosomal accumu-
lation of FC and LDL in HeLa cells. HeLa cells were transfected with
Dyn2 siRNA or scramble siRNA (control) for 48 h in LPDS medium
(LPDS) or LPDS medium and 200 mg/ml LDL (LDL). Dyn2 and actin levels
were determined by western blot (A). Cells were loaded for 6 h with
200 mg/ml LDL and stained with filipin to detect FC (C). Cells were
treated as described above with 200 mg/ml DiI-LDL (B). Images were
obtained using wide-field epifluorescence microscopy. Scale bars,
10 mm.
doi:10.1371/journal.pone.0029042.g004
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cells were incubated with LDL in the presence or in the absence of
dynasore. The kinetics of expression of the LDLR gene were
monitored by real time quantitative RT-PCR analysis in HeLa
cells (Figure 5A). As expected in cells that are in excess of
exogenous cholesterol, a potent repression of the expression of the
LDLR gene was measured as early as 5 hours after the addition of
LDL and for as long as 24 hours in control cells. In contrast, no
down-expression of the LDLR gene could be measured in cells
treated with dynasore at similar times, and LDLR expression levels
were similar to those observed in cells not supplemented with
LDL. Seven hours after LDL addition, however, the effect of
dynasore decreased progressively and the level of LDLR gene
expression resumed to control values at 24 hours. Thus, we chose
to analyze the effects of dynasore after 6 hours of LDL addition,
which corresponds to a strong repression of the sterol-sensitive
transcriptional response in control cells and to the maximal
inhibition by dynasore. At 6 hours, dynasore also strongly
inhibited the LDL-induced repression of another major sterol-
sensitive gene, HMGCoAR, whereas the repression on SREBF-2
gene expression was not observed at this time in HeLa cells
(Figure 5B). Similar results were obtained in dynasore-treated
HMDM, with a strong inhibition of the down-regulation of sterol-
sensitive genes (LDLR, HMGCoAR and to a lesser extent,
SREBF-2) induced by AcLDL (Figure 5C). These data are in
agreement with the accumulation of LDL and AcLDL in enlarged
Figure 5. Dynasore blocks sterol-sensitive genes regulation in HeLa cells and HMDM. (A) Kinetics of LDLR expression analyzed by RT-PCR.
HeLa cells were grown in LPDS medium for 48 h and further incubated for the indicated times with medium containing either LPDS, 200 mg/ml LDL,
or 200 mg/ml LDL with 80 mM dynasore. (B) The expression level of sterol-sensitive genes (LDLR, HMGCoAR and SREBF-2) was quantified after 6 h in
HeLa cells grown in LPDS, with 200 mg/ml LDL or 200 mg/ml LDL with 80 mM dynasore, as indicated. (C) The same experiment was performed in
HMDM with 50 mg/ml AcLDL. Relative quantification of LDLR, HMGCoAR, and SREBF-2 genes in HeLa cells or HMDM was expressed as fold-variation
over control (LPDS/DMSO) after normalization. All CT determinations were made in triplicate.
doi:10.1371/journal.pone.0029042.g005
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reflect a defect in the delivery of LDL-derived cholesterol to the
ER.
Dynasore prevents the esterification of exogenous LDL-
derived cholesterol
We next measured the fraction of esterified cholesterol by the
ACAT enzyme as a marker of the amount of FC being delivered
to the ER. Indeed, CE are generated from FC by the activity of
the ACAT enzyme [7]. Since this enzyme is strictly localized in the
ER membranes, the amount of cholesterol esterified by ACAT
reflects the amount of FC delivery to the ER [23,24]. Thus, we
measured by HPLC the balance between the pools of free and
esterified intracellular cholesterol. When HeLa cells were grown
under sterol starvation, cholesterol was mainly detected as FC and
esters represented less than 5% of total cholesterol (Figure 6A).
After the addition of LDL, the total amount of CE represented
more than 30% of total cholesterol. Dynasore treatment reduced
this amount by about 15%. This moderate inhibition disagrees
with the complete absence of sterol-sensitive genes repression in
dynasore treated cells as observed above. Thus, we studied
whether a fraction of the measured pool of CE may be
independent from the ER-ACAT activity. Indeed, dynasore
treatment leads to the abnormal endosomal accumulation of
LDL, which are unlikely to be de-esterified by the lysosomal
hydrolases and thus could contribute to the total intracellular pool
of CE. Therefore, we measured the total amount of CE in HeLa
cells in which ACAT activity was pharmacologically inhibited.
Under this condition, we found that the amount of CE generated
by ACAT accounted for only 38% of the total intracellular pool of
CE (Figure 6A). When cells were treated with dynasore, this
amount decreased to about 10%, which represents a 74%
inhibition of LDL-derived cholesterol esterification. We could
confirm this result by measuring the synthesis of cholesteryl
myristate by ACAT, an ester that was not initially present in our
cells. After addition of myristate, we found by HPLC that the
production of cholesteryl myristate was decreased by 80% in cells
treated with dynasore (Figure 6B).
In HMDM, dynasore treatment decreased the total amount of
CE more efficiently than in HeLa cells (Figure 6C). However, the
level of CE was initially lower in HMDM than in HeLa cells (11%
versus 35%, respectively). This could be due to different kinetics of
Figure 6. Dynasore decreases the production of cholesterol esters from LDL- or AcLDL-derived cholesterol. HeLa cells or HMDM were
respectively incubated with 200 mg/ml LDL (A) or 50 mg/ml AcLDL (C) and treated for 6 h with 80 mM dynasore or without (control). The total amount
of CE was quantified and expressed as the percent of the total amount of cholesterol. ACAT-dependent ester formation was measured with 10 mg/ml
ACAT inhibitor (grey bars). The production of cholesteryl myristate was measured in HeLa cells (B) or HMDM (D) treated or not (control) with 80 mM
dynasore. Cholesteryl myristate was expressed in nmol/mg protein. Each value is the mean of triplicate experiments.
doi:10.1371/journal.pone.0029042.g006
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Indeed, after 24 hours of incubation with AcLDL, the level of CE
in HMDM was higher and represented 40% of total cholesterol
(data not shown). Again, dynasore treatment led to a strong
decrease (90%) of the amount of CE specifically generated by
ACAT (Figure 6C) and of the incorporation of myristate into CE
(82% inhibition) (Figure 6D). Together these findings demonstrate
that the abnormal endosomal accumulation of LDL induced by
dynasore treatment results in a strong defect of FC delivery to the
ER.
Dynasore decreased cholesterol efflux in human
macrophages
Although reverse cholesterol transport (RCT) is a general
peripheral process, macrophages are the primary cells that are
overloaded with cholesterol in atherosclerotic lesions [25]. The
efficiency of cholesterol efflux, the first step of RCT from
macrophage foam cells, is determined not only by the activity of
cholesterol transporters and extracellular acceptors, but also by the
availability of cholesterol for efflux. It was therefore interesting to
test whether the abnormal sequestration of large amounts of
cholesterol in the endolysosomal compartment could affect the
cholesterol efflux capacity of HMDM. Thus, we measured
cholesterol mass efflux to either lipid-free apoA-I or to HDL
(high density lipoproteins) in HMDM loaded with AcLDL
(Figure 7A). Dynasore treatment resulted in a strong decrease of
cholesterol efflux to apoA-I (40%) and HDL (70%). Similar results
were observed when cholesterol efflux was stimulated with the
natural LXR/RXR agonists, 22OHC/9cRA (Figure 7B). The two
ABC (ATP binding cassette) members of cholesterol transporters,
ABCA1 and ABCG1 have been involved in cholesterol efflux to
lipid poor apoA-I and HDL, respectively [25,26]. We thus
examined the impact of dynasore treatment on ABCA1 and
ABCG1 gene expression. As expected, the addition of AcLDL to
HMDM led to an increase of ABCA1 and ABCG1 mRNA levels
Figure 7. Dynasore impairs cellular cholesterol efflux from HMDM. HMDM were incubated for 6 h with 100 mg/ml AcLDL with 80 mM
dynasore or without (control). The cellular cholesterol efflux to 10 mg/ml apoA-I or 15 mg/ml HDL-PL before (A) and after (B) stimulation of ABCA1 and
ABCG1 expression by the LXR/RXR agonists was quantified. Results are expressed as the percentage of the quantity of released cellular cholesterol
into the medium to the total quantity of cholesterol in cells and medium. Each value is the mean of triplicate experiments. (C) Relative quantification
of ABCA1 and ABCG1 transporter genes levels was expressed as fold-variation over control (DMSO/LPDS) after normalization. All CT determinations
were made in triplicate. (D) Passive cholesterol efflux to 1 mg/ml Ma ˆCD was quantified as above.
doi:10.1371/journal.pone.0029042.g007
Figure 8. Dynasore treatment affects M6PR distribution. (A)
Cells expressing GFP-M6PR were treated 6 h with 80 mM dynasore or
without (control). Images were obtained using wide-field epifluores-
cence microscopy. Scale bars, 10 mm.
doi:10.1371/journal.pone.0029042.g008
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was completely abolished when HMDM were treated by dynasore
(Figure 7C). Finally, we examined whether dynasore treatment
could affect the amount of cholesterol associated with the plasma
membrane, which is involved in the passive cholesterol efflux
pathway. To address this question, we used MbCD, a high-affinity
acceptor of cholesterol. Short time incubation with MbCD was
shown to remove cholesterol from the plasma membrane [27].
Under these conditions, cholesterol efflux was significantly
decreased (34%) in dynasore-treated cells (Figure 7D). Together,
these results indicate that dynasore, by affecting intracellular
cholesterol trafficking, has a major impact on several pathways
implied in active and passive cholesterol efflux.
Dynasore affects the intracellular distribution of the
mannose 6-phosphate receptor
We tested whether dynasore could affect the trafficking of other
cargos through the late endosomal network. We therefore studied
the cation-independent mannose 6-phosphate receptor (M6PR),
which constitutively recycles between late endosomes and the
Golgi complex [28]. When HeLa cells expressing a GFP tagged
M6PR were treated by dynasore, we observed that the M6PR was
not present at the Golgi complex and was localized instead in
dispersed endosomal structures (Figure 8). This result, in
agreement with a previous study [28], indicates that the effect of
dynasore was not restricted to the block of FC from the late
endosomal network but affected also cargo trafficking at this
interface.
Comparison of dynasore and U18666A treatments on
cholesterol trafficking in HeLa cells and macrophages
These results led us to compare the effects of dynasore with
U18666A, a hydrophobic amine that has been extensively used to
study cholesterol homeostasis, and more particularly cholesterol
intracellular trafficking [29]. In contrast to dynasore, we found
that U18666A treatment led to a respective 20% and 40%
increase of LDL uptake and AcLDL in HeLa cells and HMDM
(Figure 9 A and C). Accordingly, we measured an increase in the
total amount of cholesterol present in HeLa cells and HMDM
after U18666A treatment (Figures 9 B and D). The inhibition of
cholesterol egress from late endosomes and lysosomes is a well-
known effect of U18666A [29,30]. As expected, treatment with
U18666A led to the formation of swollen endosomal structures
loaded with FC in HeLa cells and HMDM (Figure 10). These
structures were part of the endolysosomal network as confirmed by
staining with Lamp1 (not shown). As a consequence, there was no
response of sterol-sensitive genes to the addition of LDL or AcLDL
in U18666A treated cells (Figures 11 A and B). In contrast to cells
Figure 9. Effect of U18666A on LDL uptake and total cholesterol in HeLa cells and HMDM. LDL uptake was measured in HeLa cells (A) and
HMDM (C) after incubation at 37uC for 4 h with 0–200 mg/ml DiI-LDL or 0–100 mg/ml DiI-AcLDL, respectively, with 3 mg/ml U18666A or without
(control). The amount of endocytosed DiI-LDL and DiI-AcLDL was measured by flow cytometry. Values represent the mean 6 SD of triplicate
experiments. Total cholesterol was quantified in HeLa cells (B) and HMDM (D) after 4 h of LDL uptake with 3 mg/ml U18666A or without (control).
Each value is the mean 6 SD of triplicate experiments and expressed as nanomoles per mg of cell proteins.
doi:10.1371/journal.pone.0029042.g009
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percentage of CE in U18666A-treated cells (Figures 11 C and D).
The measure of CE in cells loaded with cholesterol in the presence
the ACAT inhibitor revealed that the fraction of CE specifically
generated by ACAT was 54% of the total intracellular pool of CE.
When cells were treated with U18666A, the amount of CE
generated by ACAT was decreased by 90%. Likewise the
incorporation of myristate into CE was strongly inhibited by
U18666A (Figure 11 E and F).
Finally, we also measured the effects of U18666A on cholesterol
efflux. As shown in Figures 12 A and D, the cellular cholesterol
efflux to apoA-I, HDL, and MbCD was decreased by 42%, 58%,
and 37%, respectively when macrophages were treated with
U18666A. A similar decrease was measured in AcLDL-loaded
macrophages after stimulation by the LXR/RXR agonists,
22OHC/9cRA (Figure 12B). Like dynasore, U18666A completely
blocked the increase of ABCA1 and ABCG1 mRNA levels in
response to the addition of AcLDL in HMDM (Figure 12C).
Discussion
Dynasore is a small drug that was identified through a chemical
screen designed for inhibitors of the dynamin GTPase activity
[10]. Because of its cell membrane permeability and reversibility,
dynasore has since been extensively used to block in a selective and
powerful manner the different endocytic pathways that rely on the
dynamin GTPase. In a previous work based on the expression of
the K44A inactivated mutated form of dynamin, we could
demonstrate that dynamin activity was also required for proper
sorting of cholesterol in the endolysosomal network of HeLa cells.
K44A dynamin expression led to the inhibition of free cholesterol
endosomal egress to the ER, which instead accumulated into
swollen endosomes of the endolysosomal network. As a result, the
sterol-sensitive gene regulation was inhibited [9].
In this study, we took advantage of the cell permeability of
dynasore to further extend our understanding of cholesterol
intracellular trafficking in human macrophages. We chose to work
on HMDM isolated from peripheral blood since available mouse
or human macrophages cell lines do not entirely reproduce the
characteristics of primary cultured HMDM. The monocytes were
differentiated into macrophages by hM-CSF instead of hGM-CSF
since it favors the expression of cell surface markers that are closer
to those found in macrophages from atherosclerotic lesions [31].
AcLDL were used instead of native LDL since AcLDL uptake is
20-fold higher in human macrophages [32]. Indeed, the class A
macrophage scavenger receptor SR-A accounts for the majority of
AcLDL uptake, a pathway that is unregulated and can lead to the
intracellular accumulation of large amounts of cholesterol and
foam cell formation. In contrast, the uptake of native LDL is
minor and regulated in macrophages [33]. Moreover, Wang et al.
have shown in macrophages that AcLDL-delivered cholesterol is
preferentially transported into the late endosomal network
whereas LDL-derived cholesterol is preferentially transported to
the recycling compartment [34]. In this study, we show that
dynasore recapitulates the effects of the K44A dynamin mutant on
cholesterol homeostasis that we have first described in HeLa cells.
Dynasore, however, was more efficient to block LDL uptake than
the K44A mutant, which probably reflects the more homogenous
cell distribution of the drug. Interestingly, the inhibition of AcLDL
uptake by dynasore was less efficient in human macrophages. This
is in agreement with the lesser inhibition of AcLDL uptake that
was also reported in HMDM after down-expression of clathrin
[35]. Macrophages can use several alternative pathways such as
macropinocytosis or caveolae for the uptake of AcLDL [35,36].
Our data suggest that the dynamin-independent endocytic
pathways are the main contributors to AcLDL uptake in HMDM.
In contrast to dynasore, U18666A leads to an increase of LDL
uptake in both HeLa cells and HMDM. This increase, which is
much higher in HMDM cells, can be inhibited by dynasore (not
shown) indicating that U18666A up-regulates LDL uptake
through the classical endocytic pathways. The increased LDL
uptake is probably due to the known increased expression of LDL
receptors resulting from the inhibition of FC delivery to the ER by
U18666A. Dynasore treatment, which also leads to an increase of
LDL receptor gene expression (Figure 4), does not result however
in increased LDL uptake, because of its inhibitory effect on LDLR
endocytosis through clathrin-coated pits.
We show that dynasore blocks the delivery of exogenous LDL-
derived cholesterol from the endolysosomal network to the ER,
resulting in the inhibition of both sterol-sensitive genes regulation
and cholesterol esterification. Similar findings were found in cells
where dynamin 2 was down-expressed by RNAi treatment
confirming the specificity of dynasore effect at the late endosomal
network. Interestingly, dynasore and U18666A present the same
effects on cholesterol membrane trafficking and sterol-sensitive
genes regulation.
The kinetics of the inhibition of LDL induced sterol-sensitive
genes down-regulation showed that dynasore activity was maximal
at 6 hours. We observed a progressive decrease of dynasore effect
with time, an effect not observed with U18666A. Whether this is
due to an inactivation of the drug with time or to the delivery of
Figure 10. Effects of U18666A on the intracellular distribution
of FC and LDL in HeLa cells and HMDM. HeLa cells and HMDM
were respectively incubated for 6 h with 200 mg/mL LDL (A) or 50 mg/
ml AcLDL (C) with 3 mg/ml U18666A or without (control) and stained
with filipin to detect FC. (B–D) HeLa cells and HMDM were respectively
incubated for 6 h with 200 mg/ml DiI-LDL (B) or 50 mg/ml DiI-AcLDL (D)
with 3 mg/ml U18666A or without (control) and processed to visualize
LDL distribution. Images were obtained using wide-field epifluores-
cence microscopy.
doi:10.1371/journal.pone.0029042.g010
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this context, it is interesting that the inhibition of LDL uptake by
dynasore persisted for 24 hours suggesting that the drug was still
active at this time (data not shown).
Different cholesterol efflux pathways have been described that
occur either by a non regulated diffusive process, or actively
mediated by SR-BI and ABC transporters [26]. Recent studies
indicate that ABCA1 and ABCG1 are the main contributors to the
Figure 11. U18666A inhibits ACAT activity and sterol-sensitive genes regulation in HeLa cells and HMDM. Cells were grown in LPDS
medium for 48 h and further incubated for 6 h with 200 mg/ml LDL (A) or 50 mg/ml AcLDL (B) with 3 mg/ml U18666A or without (control). Relative
quantification of LDLR, HMGCoAR, and SREBF-2 genes in HeLa cells (A) or HMDM (B) was expressed as fold-variation over control (LPDS/DMSO) after
normalization. All CT determinations were made in triplicate. The total amount of CE was quantified HeLa cells (C) and in HMDM (D) and expressed as
the percent of the total amount of cholesterol. ACAT-dependent ester formation was measured with 10 mg/ml ACAT inhibitor (grey bars). Cholesteryl
myristate formation was measured in HeLa cells (E) or HMDM (F) with 3 mg/ml U18666A or without (control). Cholesteryl myristate was expressed in
nmol/mg protein. Each value is the mean of triplicate experiments.
doi:10.1371/journal.pone.0029042.g011
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[34,37,38]. Our data show that the cholesterol efflux mediated
by ABCA1 and ABCG1 was impaired in dynasore-treated
HMDM, even after stimulation with the LXR/RXR agonist.
Similar results were obtained with U18666A. It has been shown
that the endolysomal sequestration of LDL-derived cholesterol in
NPC
2/2 cells altered cholesterol efflux by reducing the amount of
cholesterol substrate available for ABCA1 and by defective
synthesis of LDL-cholesterol-derived side-chain oxysterols
[39,40]. The decreased production of oxysterols, which are
endogenous LXR ligands, results in reduced ABCA1 and ABCG1
expression and lower cholesterol efflux activity [41]. 27 hydro-
xycholesterol is the most abundant oxysterol present in macro-
phages. A key step in 27 hydroxycholesterol synthesis is the
delivery of cholesterol to mitochondria where is present the sterol-
27 hydroxylase CYP27. It is therefore tempting to speculate that
the decrease of ABCA1 and ABCG1 gene expression is due to a
decreased delivery of cholesterol to mitochondria. Alternatively,
the decrease of cholesterol efflux mediated by ABCA1 and
ABCG1 could be the consequence of a reduction of the pool of FC
at the plasma membrane since it is a preferential site to collect FC
coming from the endolysosomal compartment.
The role of dynamin in endolysosomal sorting remains poorly
documented. We show here that dynasore treatment affects not
only cholesterol trafficking but also the intracellular distribution of
the M6PR. A recent work has shown that dynamin 2 controlled
the exit of the EGFR from late endosomes through its association
with CIN85 [42]. Altogether these data demonstrate that dynamin
controls trafficking events within the endolysosomal system
presumably through the scission of vesicular buds originating
from early and/or late endosomes and affects several cargos that
use this pathway.
In conclusion, we have shown that the pharmacological
inhibition of the dynamin GTPase activity by dynasore leads
rapidly to the abnormal endosomal sequestration of FC and LDL,
resulting in defective sterol-sensitive genes regulation and
cholesterol efflux in HMDM. These results demonstrate that
dynasore can be used to block the egress of FC from the
endolysosomal network. Dynasore therefore represents an inter-
esting alternative to U18666A and will be useful to better
understand the complexity of cholesterol trafficking and homeo-
stasis at the late endosomal interface.
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Figure 12. U18666A impairs cellular cholesterol efflux from HMDM. Cells were incubated with 100 mg/ml AcLDL for 6 h and treated with
3 mg/ml U18666A or without (control). The cellular cholesterol efflux to 10 mg/ml apoA-I or 15 mg/ml HDL-PL before (A) and after (B) stimulation of
ABCA1 and ABCG1 expression by the LXR/RXR agonists was quantified. Results are expressed as the percentage of the quantity of released cellular
cholesterol into the medium to the total quantity of cholesterol in cells and medium. Each value is the mean of triplicate experiments. (C) Relative
quantification of ABCA1 and ABCG1 transporter genes levels expressed as fold-variation over control (DMSO/LPDS) after normalization. All CT
determinations were made in triplicate. (D) Passive cholesterol efflux to 1 mg/ml Ma ˆCD was quantified as above.
doi:10.1371/journal.pone.0029042.g012
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